Evidence map›Paper›PMID 42272105›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2026

Antibody format matters: A comparative analysis of VHH and scFv domains reveals superior in vivo CAR T cell function with VHH domains.

Alexander Kinna, Preeta Datta, Reyisa Bughda, Farhaan Parekh, Mathew Robson, Ram Jha, Phillip Wu, Ian Scott, Elizabeth Hogben, Oliver Amin and 17 more

Abstract read
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Alexander KinnaAutolus Therapeutics Plc, London W12 7FP, UK.
Preeta DattaAutolus Therapeutics Plc, London W12 7FP, UK.
Reyisa BughdaAutolus Therapeutics Plc, London W12 7FP, UK.
Farhaan ParekhAutolus Therapeutics Plc, London W12 7FP, UK.
Mathew RobsonAutolus Therapeutics Plc, London W12 7FP, UK.
Ram JhaAutolus Therapeutics Plc, London W12 7FP, UK.
Phillip WuAutolus Therapeutics Plc, London W12 7FP, UK.
Ian ScottAutolus Therapeutics Plc, London W12 7FP, UK.
Elizabeth HogbenAutolus Therapeutics Plc, London W12 7FP, UK.
Oliver AminAutolus Therapeutics Plc, London W12 7FP, UK.
Gordon Weng-Kit CheungDevelopmental Biology and Cancer Department, The Cancer Institute, Paul O'Gorman Building, University College London, London WC1E 6DD, UK.
Warren HazeltonDevelopmental Biology and Cancer Department, The Cancer Institute, Paul O'Gorman Building, University College London, London WC1E 6DD, UK.
Zulaikha AkbarAutolus Therapeutics Plc, London W12 7FP, UK.
Katarina LambAutolus Therapeutics Plc, London W12 7FP, UK.
Emily MackenAutolus Therapeutics Plc, London W12 7FP, UK.
Chris AllenAutolus Therapeutics Plc, London W12 7FP, UK.
Sofi PanovskaAutolus Therapeutics Plc, London W12 7FP, UK.
Lisa HoganAutolus Therapeutics Plc, London W12 7FP, UK.
Mohamed El-KholyAutolus Therapeutics Plc, London W12 7FP, UK.
Reevesh ShresthaAutolus Therapeutics Plc, London W12 7FP, UK.
Jonathan PopplewellCarterra Inc, Salt Lake City, UT 84103, USA.
Evangelia KokalakiAutolus Therapeutics Plc, London W12 7FP, UK.
James SillibourneAutolus Therapeutics Plc, London W12 7FP, UK.
Simon ThomasAutolus Therapeutics Plc, London W12 7FP, UK.
Shimobi OnuohaAutolus Therapeutics Plc, London W12 7FP, UK.
Mathieu FerrariAutolus Therapeutics Plc, London W12 7FP, UK.
Martin PuleAutolus Therapeutics Plc, London W12 7FP, UK; Developmental Biology and Cancer Department, The Cancer Institute, Paul O'Gorman Building, University College London, London WC1E 6DD, UK. Electronic address: m.pule@autolus.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor (CAR) T cells require an extracellular targeting domain for antigen specificity, typically an scFv. VHH antibodies are emerging as alternative CAR binding regions due to their reduced size, improved stability, and CDR3 loop architecture. Herein, we generated and compared VHH and scFv antibodies targeting CD123, via immunized phage display libraries, selecting ten antibody pairs based on comparable domain targeting and kinetic profiles (K

Indexed as

Receptors, Chimeric AntigenSingle-Chain AntibodiesSingle-Domain AntibodiesT-LymphocytesAnimalsCell Line, TumorHumansImmunotherapy, AdoptiveInterleukin-3 Receptor alpha SubunitLeukemia, Myeloid, AcuteMiceProtein DomainsXenograft Model Antitumor AssaysInterleukin-3 Receptor alpha SubunitReceptors, Chimeric AntigenSingle-Chain AntibodiesSingle-Domain AntibodiesantibodyCARCD123IL3RAscFvsVHHT cellVHH

Identifiers

PMID42272105
PMCPMC13555534

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.